Montelukast Accord

Montelukast, the active ingredient in Montelukast Accord, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is indicated for the long‑term management of asthma, relief of allergic rhinitis symptoms, and prevention of exercise‑induced bronchoconstriction in both adult and pediatric patients as prescribed by a qualified healthcare professional.

GNH USA supplies Montelukast Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and tertiary care centers worldwide, including both public and private healthcare networks.

Montelukast acts on the leukotriene pathway to control airway inflammation and bronchoconstriction.

Asthma: improves long‑term control of symptoms and reduces exacerbations. Allergic rhinitis: alleviates nasal congestion, sneezing and itching associated with seasonal or perennial allergens. Exercise‑induced bronchoconstriction: prevents airway narrowing triggered by physical activity.

Montelukast may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache - Abdominal pain - Cough - Nausea

Serious or Rare Side Effects: - Angioedema - Neuropsychiatric events (e.g., agitation, depression, suicidal thoughts) - Hepatic injury

Montelukast should be used with attention to specific safety considerations. - Dose adjustment: not required for renal impairment but use caution in severe hepatic impairment. - Acute asthma: not indicated for immediate relief of bronchospasm; prescribe a rescue inhaler. - Pregnancy: only if potential benefit justifies potential risk to fetus. - Hypersensitivity: discontinue if signs of allergic reaction occur. - Store below 25°C: keep in original packaging, protect from moisture and light.

Montelukast may interact with other medicines; review concomitant therapy.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir): may increase montelukast plasma concentrations. - Phenobarbital or rifampin: may reduce efficacy by inducing metabolism.

Moderate Interactions (Monitor Closely): - NSAIDs: may increase risk of rash. - Antidepressants (e.g., fluoxetine): possible additive neuropsychiatric effects. - Warfarin: monitor INR as montelukast may affect coagulation parameters.